Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology portfolio and expand its business prospects in the U.S. and Europe.
House Republicans introduced a proposal seeking to cut Medicaid spending by hundreds of billions of dollars. Healthcare leaders are slamming the budget plan, highlighting that it would result in millions of people losing coverage, as well as a surge in uncompensated care for providers.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
SpringWorks Therapeutics’ Gomekli is now FDA approved for treating tumors caused by the rare genetic disorder neurofibromatosis type 1. The approval comes as SpringWorks has emerged as a potential acquisition target.
Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA twice turned back applications for the drug/device combination product.
Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a key pathway in the peripheral nervous system.
Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
AstraZeneca’s Datroway, an antibody drug conjugate (ADC), is now FDA approved for advanced cases of breast cancer that is HR positive and HER2 negative. Datroway targets TROP2, the same cancer protein addressed by Trodelvy, a Gilead Sciences ADC also approved for breast cancer.
AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an initial treatment for this type of blood cancer.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions.
The Affordable Care Act's enhanced subsidies are at risk of expiring at the end of 2025, and healthcare leaders are worried about what could happen if Congress doesn’t renew them. For instance, more Americans would become uninsured, premiums would increase, and hospitals would be saddled with more bad debt due to uncompensated care.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for most solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration.
President-elect Donald Trump recently appointed former Paypal executive David Sacks as the White House’s first-ever czar for AI and cryptocurrency. Ryan Tarzy — CEO of Avandra Imaging, a federated network for de-identified imaging data — thinks this appointment could help accelerate the pace of innovation in the healthcare industry.
Zepbound’s clinical tests in obstructive sleep apnea showed improvement in breathing disruptions that were accompanied by reductions in body weight. The new approval gives the Eli Lilly medicine the opportunity to become a blockbuster seller in yet another indication.
Congress released a stopgap funding bill with a significant healthcare package, and provider groups are reacting favorably. They are mainly applauding provisions that reign in PBMs’ business practices, extend telehealth flexibilities, and boost payments to hospitals and physicians.